

Research Article

Comparison of Sleep Quality before and after Chemotherapy in Locally Advanced Non-small Cell Lung Cancer Patients: A Prospective Study

N. Belloumi ¹, S. Maalej Bellaj,^{2,3} I. Bachouche,¹ F. Chermiti Ben Abdallah,^{1,3} and S. Fenniche^{1,3}

¹Pulmonology Department Pavilion 4 Abderrahman Mami Hospital Ariana, Tunisia

²Pulmonology Department Pavilion D Abderrahman Mami Hospital Ariana, Tunisia

³University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia

Correspondence should be addressed to N. Belloumi; nidhalbelloumi@gmail.com

Received 1 March 2020; Revised 20 April 2020; Accepted 4 May 2020; Published 20 July 2020

Academic Editor: Giora Pillar

Copyright © 2020 N. Belloumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Preservation of sleep quality is a modifiable and treatable factor, which may enhance the patient's adherence to other supportive and palliative care procedures. The outcome of sleep disturbances in lung cancer patients before and after treatment aren't reported. The aim of this study was to investigate changes in sleep quality before and after chemotherapy in locally advanced or metastatic NSCLC patients. **Methods.** It was a prospective study including 64 patients with stage III or IV non-small-cell lung cancer. Patients answered the Tunisian dialectal version of the following questionnaires: PSQI and QLQ-C30 in order to evaluate, respectively, the sleep quality and the quality of life. The assessments took place before chemotherapy and then repeated after the chemotherapy course was over. **Results.** The mean age was 62.9 years. All patients were active smokers. Before chemotherapy, there were 10 patients (15%) with poor sleep quality. The most frequent complaints were daytime sleepiness (70%) and nocturnal arousals (100%). After chemotherapy, the mean PSQI score increased from 2.9 to 5.4, and 45% of all patients had poor sleep quality. Most frequent complaints were the extension of sleep latency (69%), daytime sleepiness (98%), and nocturnal arousals (100%). Predicting factors of sleep disturbance according to statistical univariate analysis were delayed diagnosis confirmation ($p = 0.05$), delayed treatment onset ($p < 10^{-3}$), depressive mood ($p = 0.001$), and anxious mood ($p = 0.001$). Multivariate analysis had shown a significant and independent correlation between sleep quality and shortened diagnosis and treatment delays. Sociodemographic parameters, clinical parameters, and factors related to treatment procedure had no correlation with sleep quality. **Conclusions.** Our study demonstrates the persistence and potential intensity worsening of sleep disturbances in advanced stage non-small-cell lung cancer patients. We, hereby, reported a statistical correlation between sleep quality and quality of life in our patients.

1. Background

According to the Global Cancer Observatory, worldwide incidence was 2.09 million cases in 2018. It is also responsible of 1.76 million deaths per year. Lung cancer represents 11.6% of all malignant tumor incidence and makes 18.4% of mortality of all cancers. It has so, the highest mortality rate in men and the second-highest mortality rate in women [1, 2]. In Tunisia, tobacco smoking is still rising. Lung cancer inci-

dence in men is 63.5 cases/100000 in the period 2004-2006. Incidence in women is 5.1 cases/100000 [3]. Diagnosis announcement is followed therefore by a psychological impact with variable intensity and various manifestations. Chemotherapy is proposed in stage IV of the disease if there are no contraindications. Its impact on the general status, quality of life, and sleep quality is scarcely reported [4-6]. These interactions between burdensome therapeutic protocols and quality of life or sleep were reported in other cancer

TABLE 1: Clinical characteristics of the lung cancer patients.

	Number	%
Past medical history		
COPD	21	32.8
Pulmonary tuberculosis	10	15.6
Hypertension	23	35.9
Diabetes mellitus	9	14.1
Gastroduodenal ulcer	10	15.6
Benign prostatic hyperplasia	8	12.5
Performance status (PS)		
0	17	26.6
1	23	35.9
2	22	34.4
3	2	3.1
Stage		
IIIa	4	6.3
IIIb	13	20.3
IIIc	9	14.1
IVa	10	15.6
IVb	14	21.9
IVc	14	21.9
Delays (days)		
	Mean	Median
1 st X Ray–1 st consultation	18.5	17
1 st consultation–diagnosis	40.6	32

types [7–9]. Preservation of sleep quality is a major palliative care goal increasingly mentioned in advanced cancer management. Nevertheless, sleep quality deterioration before and after chemotherapy has not been studied. The aim of this study was to report various sleep disturbances in advanced-stage lung cancer patients and their outcome after chemotherapy and/or radiotherapy. We aimed also to assess the correlation between sleep quality and quality of life.

2. Methods

2.1. Design. This was a single-arm prospective cohort study conducted in the pulmonology department Pavilion 4 in Ariana Hospital, Tunisia. The follow-up period was the duration of the chemotherapy course.

2.2. Patients. We included all NSCLC patients in stage III to IV of the disease according to the 8th edition of TNM classification [10].

Inclusion criteria were confirmed NSCLC with histological proof, stage III or IV of the disease, prescription of a chemotherapy course, written informed consent to receive chemotherapy course, and written informed consent to participate in the study.

Noninclusion criteria were known sleep disturbance prior to lung cancer diagnosis, pharmacological treatment interfering with sleep quality, severe pain with intensity greater than 6/10 in visual analogical scale (VAS), and leading to the prescription of oral opioid therapy.




FIGURE 1: Mean Pittsburgh Sleep Quality Index (PSQI) score at baseline and after chemotherapy.

Exclusion criteria were the death of the patient during the chemotherapy course, worsening of the general status leading to a medical decision to stop the chemotherapy, nonadherence of the patient to chemotherapy whatever was the reason, withdrawal of consent to participate in the study, and starting a prescription of any treatment interfering with sleep quality: morphine, neuroleptic, or antiepileptic treatment.

2.3. Methods and Assessment Tools. The inclusion period lasted from February to August 2018. We included consenting patients who fulfilled the inclusion criteria. After announcing the diagnosis and the prognosis of the disease, we planned an appointment with the patient before starting the chemotherapy protocol. In this meeting, we made our first evaluation via questionnaires of the quality of life and sleep quality. We gathered also sociodemographic and clinical data. After the chemotherapy course, if there were no exclusion criteria, a second evaluation with the same methods was done. Side effects of chemotherapy administration were classified as mentioned in the “Common Terminology Criteria for Adverse Events” [11].

2.3.1. Sleep Quality Assessment. Pittsburgh Sleep Quality Index (PSQI) was used. It contains nineteen questions about seven dimensions of sleep disturbance patterns: global subjective quality of sleep—sleep latency—sleep duration—sleeping efficiency—sleep and wake disturbances—use of sleep medication—daytime dysfunction or sleepiness [12]. Every dimension is evaluated from 0 to 3 according to the patient’s answers. The score reflects the disturbance severity. The seven dimensions scores were combined to give a global score ranging from 0 to 21, with greater scores indicating poorer sleep quality. When the PSQI score is greater than 5, sleep quality is considered as poor. The PSQI was validated for cancer patients [13]. We used an Arabic Tunisian dialectal version of PSQI, which is not validated yet, to be easily answered by patients (Appendix 1–Appendix 2).

TABLE 2: Number and percent of sleep disturbances in poor sleep quality patients before and after chemotherapy.

Sleep disturbances	Baseline ($n = 10$)		After chemotherapy ($n = 29$)		p
Sleep hours < 6 hours	2 patients	20%	12 patients	41.4%	0.06
Sleep hours > 9 hours	4 patients	40%	5 patients	17.2%	0.09
Daytime sleepiness	7 patients	70%	26 patients	89.6%	0.14
Prolonged sleep latency	6 patients	60%	20 patients	68.9%	0.33
Delayed sleep phase disorder	0	0	1 patient	3.4%	0.18
Advanced sleep phase disorder	1 patient	10%	0	0	0.66
Nocturnal arousals	10 patients	100%	29 patients	100%	0.29

TABLE 3: Outcome of the mean scores of QLQ-C30 items after chemotherapy.

Items/symptoms	Before chemotherapy		After chemotherapy		p
	Mean	Median	Mean	Median	
Fatigue	32.3	33.3	34.9	33.3	0.61
Nausea	3.5	0	15.4	0	0.04
Pain	21.4	0	13	0	0.16
Dyspnea	45.7	33.3	41.7	33.3	0.37
Insomnia	13	0	22.9	0	0.05
Anorexia	31.2	0	41.2	66.7	0.08
Constipation	10	0	11	0	0.43
Diarrhea	0	0	0.5	0	0.10
Financial difficulties	42.7	33.3	44.8	33.3	0.52
Mean coefficient of symptom items	22	20.7	25.4	26.8	0.47
Performance items					
Physical functioning	64.2	66.7	12.7	13.3	0.001
Role functioning	76.6	83.3	73	83	0.47
Emotional functioning	71	66.7	65.7	66.7	0.21
Cognitive functioning	78.6	83.3	69	75	0.09
Social functioning	68	72.7	56	50	0.05
Mean coefficient of performance items	71.3	72.5	55.3	58.5	0.09

2.3.2. Health-Related Quality of Life Assessment. We used the QLQ-C30 questionnaire, elaborated by the European organization of research and treatment of cancer [14–19]. The questionnaire included thirty forced-choice questions (Appendix 3–Appendix 4), classified as follows:

- (i) Symptom items (9 items, 13 questions): fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties
- (ii) Functional items (5 items, 15 questions): physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning
- (iii) Global health item (1 item, 2 questions)

Each question is answered by a score ranging from 1 to 4. For every item, a score is calculated according to answers, ranging from 0 to 100%. Mean scores of symptom items, functional items, and global health items are, then, obtained. We used an Arabic Tunisian dialectal version of QLQ-C30 which is widely used in Tunisia but still not validated [18].

2.4. Ethical Aspect. In their inclusion, patients were asked to sign a written consent. The study protocol was discussed then accepted on November 9th 2018, by the ethics committee of Abderrahmen Mami (study protocol No 10/2018).

2.5. Statistical Analysis. We performed initially a descriptive statistical analysis to get frequencies, percentages, and mean sociodemographic parameters. Quantitative and objective assessment of sleep quality and quality of life was provided. Then, a comparative statistical analysis was conducted to identify correlations between mean scores of questionnaires or percentages (Student t -test or nonparametric tests) and between categorical parameters or frequencies (Qui square test).

3. Results

We enrolled 107 patients during the study. Exclusion criteria were decisive in 53 cases. We kept 64 cases in the data collecting step. The mean age of our patients was 62.9 ± 8.18 years [42–85]. All patients were active smokers. Current smokers represented 48.4% of all patients. Most frequent past medical

TABLE 4: Outcome of the mean coefficients before then after chemotherapy.

		Before chemotherapy		After chemotherapy		<i>p</i>
		Mean	Median	Mean	Median	
Mean coefficient of symptom items						
All patients (<i>n</i> = 64)		22	20.7	25.4	26.8	0.31
	0	12.4	11.1	17.5	12.3	0.14
Performance status	1	21.5	22.2	24.2	26.5	0.19
	2	29.4	30.8	32.5	31.5	0.30
	3	27.1	27	25.9	25.9	0.36
PSQI score	>5 (<i>n</i> = 29)	20.2	18.5	18.6	19.1	0.55
	≤5 (<i>n</i> = 35)	31.8	33.3	33.5	32.1	0.34
BMI	≤18 (<i>n</i> = 6)	29.9	33.3	31.4	33	0.42
	>18 (<i>n</i> = 58)	20.7	18.5	24.7	26.5	0.18
TNM stage	III (<i>n</i> = 26)	20	19	18.5	20.3	0.39
	IV (<i>n</i> = 38)	26	26	29.4	30.6	0.28
Mean coefficient of performance items						
Tous les patients (<i>n</i> = 64)		71.3	72.5	55.3	58.5	0.08
	0	79.1	86.6	62.5	70.7	0.038
PS	1	76.8	79	60.3	65.4	0.13
	2	62.7	61.8	46	45	0.11
	3	37.5	37.5	40.9	40.9	0.23
PSQI score	>5 (<i>n</i> = 29)	50.5	49	46	41.3	0.16
	≤5 (<i>n</i> = 35)	75.2	78.7	63	67	0.09

history were hypertension (23%) and COPD (21%), as mentioned in Table 1. Eastern Cooperative Oncology Group Performance Status (ECOG PS) in the 1st consultation was less than 2 in 62.5% of all patients.

From the 1st consultation to the obtaining of histological confirmation, the mean delay was 40.6 days. Using the TNM 9th edition, 59.4% of patients were in stage IV of the disease (Table 1). Four cycles of palliative chemotherapy was administered for all stage IV patients (59%). Curative concomitant chemoradiation was performed in 3 patients (4.7%). Chemotherapy associated to sequential radiotherapy was administered for 11 patients (17.2%). Curative chemotherapy without additional thoracic radiotherapy was administered for 12 patients (18.7%).

3.1. Sleep Quality–PSQI Questionnaire Analysis. Ten patients (15.6% of all patients) had poor sleep quality before chemotherapy. After chemotherapy, 29 patients (45.3%) had poor sleep quality (Figure 1). PSQI score of all patients went from 2.9 before treatment to 5.4 after treatment ($p = 0.001$). Most reported sleep disturbances were daytime sleepiness, prolonged sleep latency, and nocturnal arousals (Table 2).

3.2. QLQ-C30 Questionnaire Analysis. High scored symptom items before chemotherapy onset were dyspnea (45.7%), anorexia (31.2%), and financial difficulties (42.7%). These findings showed the intensity of these complaints in our patients. Statistically significant rise after chemotherapy was noted in nausea and insomnia mean coefficients which reflected a worsening in these complaints (Table 3). Mean coefficient of symptom items of all patients was 22% before chemotherapy onset, then became 25.4% after chemother-

apy. The coefficient was significantly less in patients with PSQI score < 5 and Performance Status score < 2.

Performance item mean scores before and after chemotherapy were nearly similar, between 64.2% and 78.6%. Statistically significant decrease after chemotherapy was mentioned in “physical functioning” and “social functioning” (Table 3). Mean coefficient of performance items of all patients was 71.3% before chemotherapy onset, then became 55.3% after chemotherapy. The coefficient was significantly better in patients with PSQI score < 5 and Performance Status score < 2. There was a statistically significant fall after chemotherapy in the mean coefficient of performance items of patients with preserved Performance Status score (Table 4).

3.3. Predictive Factors of Poor Sleep Quality: (Table 5). Patients with good sleep quality and patients with bad sleep quality had a mean age of 62.9 years both. Clinical and demographic factors had no statistically significant effect on sleep quality in our patients (age, rural origin, histological subtype, disease stage, metastases, and their location).

Patients with poor sleep quality had a mean delay between their 1st consultation and histological confirmation significantly longer than patients with good sleep quality (47.2 days vs. 32.5 days; $p = 0.05$). As well, patients with poor sleep quality had a mean delay between histological confirmation and treatment onset significantly longer than patients with good sleep quality (28.1 days vs. 15.7 days; $p = 0.0001$).

Anxiodepressive mood was more frequently noted in poor sleep quality patients. Correlation between sleep quality and mood disturbances was statistically confirmed ($p = 0.001$). Factors related to treatment procedure (molecules of

TABLE 5: Predictive factors of sleep quality–univariate statistical analysis.

		Good sleepers	Poor sleepers	<i>p</i>
Mean delays				
	1 st consultation -histological confirmation (days)	47.2	32.5	0.05
	Histological confirmation–treatment onset (days)	28.1	15.7	0.0001
Disease-related parameters				
Stage	III (%)	41.4	40	0.80
	IV (%)	58.6	60	
Histology	Adenocarcinoma (%)	58.6	54.3	0.57
	Squamous cell carcinoma (%)	27.6	34.3	
	Nonsmall cell carcinoma (%)	13.8	11.4	
Metastasis	Yes (%)	58.6	57.2	0.55
	No (%)	41.4	42.8	
Cerebral metastasis	Yes (%)	17.2	14.3	0.64
	No (%)	82.8	85.7	
Treatment-related parameters				
Chemotherapy course rate	One day per cycle (%)	13.8	17.2	0.49
	Two days per cycle (%)	86.2	82.8	
Hospitalisation during course	Inpatient (%)	34.5	31.4	0.71
	Outpatient (%)	65.5	68.6	
Grade IV complication	Yes (%)	20.7	37	0.09
	No (%)	79.3	63	
Sleep quality	Humor quality	Number of patients	%	<i>p</i>
PSQI > 5	Normal	3 patients	10.4%	0.001
	Depression	17 patients	58.6%	
	Anxiety	9 patients	31%	
PSQI ≤ 5	Normal	28 patients	80%	0.001
	Depression	5 patients	14.3%	
	Anxiety	2 patients	5.7%	

TABLE 6: Predictive factors of sleep quality–multivariate statistical analysis.

Variable	Univariate analysis	Multivariate analysis		<i>p</i>
	<i>p</i>	Odds ratio adjusted	IC = 95% for Exp (B)	
Mean delay to histological confirmation	0.05	0.89	0.83–0.96	0.004
Mean delay to treatment onset	0.0001	1.37	1.12–1.67	0.002
Chemotherapy complications	0.09	1.79	0.46–6.95	0.39
Depressive humor	0.001	1.60	0.59–4.34	0.35
Anxious humor	0.001	3.2	0.68–15.09	0.14

chemotherapy used on the first line, number of chemotherapy courses, in-patient or outpatient administration of treatment, and complication's occurring or severity) had no effect on sleep quality in our patients. Statistical multivariate analysis has shown an independent and significant correlation between sleep quality and therapeutic management delays (Table 6).

4. Discussion

Several key points distinguished our study and made its strength. The objective to identify predictive factors of sleep quality in cancer patients, its impact on quality of life, and its correlation with disease prognosis was reported by several

TABLE 7: Prevalence of insomnia in cancer patients.

Author	Prevalence
Delgado-Guay et al. [33]	85%
Beck et al. [34]	65%
Silberfarb et al. [28] lung cancer	50.3%
Silberfarb et al. [28] breast cancer	51%
Mansano-Schlosser and Ceolim [35]	47.4%
Our study: before chemotherapy	15.6%
Our study: after chemotherapy	45.3%

TABLE 8: Quality of life assessment and its correlation to sleep quality.

Author	Questionnaire	Type of cancer	Conclusion
Kerner et al. [36]	QLQ-C30 and ESAS	Breast or endometrium cancer	Enhancement of quality of life after CIM
Fortmann et al. [37]	HRQOL	All types of cancer/teenager patients	Correlation between quality of life, asthenia, and insomnia
Beck et al. [34]	MOS PCS et MOS MCS	Breast/stage I to IIIA	Correlation between quality of life, physical, and mental health
Trudel-Fitzgerald et al. [38]	Multidimensional fatigue inventory	Resected cancers of all types	Adjuvant treatment is correlated with more depression, anxiety, insomnia, asthenia, and pain
Armbruster et al. [39]	SF36	Endometrium/early stages	Correlation between mental health and sleep quality
Inhestern et al. [32]	SF8 et FAD-GF	All cancer types survivors	Several items (social and familial support) are correlated to anxiety and depression
Our study	QLQ-C30 and PSQI	Lung/advanced stages	Several quality of life items (nausea, insomnia, physical performance) worsened after chemotherapy

CIM: Complementary integrative medicine ESAS: Edmonton Symptom Assessment Scale; FAD-GF: general functioning scale of the Family Assessment Device; HR-QOL: Health related-Quality of life; MOS MCS: Medical Outcomes Study Mental Component Score; MOS PCS: Medical Outcomes Study Physical Component Score; SF36: Short form.

studies [4, 6, 20, 21]. The correlation between quality of life and intensity of disease symptoms was previously established [20, 22]. Several studies also described a noticeable and sometimes unique correlation between quality of life and pain intensity. Strong recommendations derived from these studies to initiate early measurements to preserve quality of life and to control pain in cancer patients. Our methodology was to exclude patients with great pain levels, patients with poor general health, and patients on specific treatment interacting with sleep quality. That allowed us to select a coherent cohort of patients to evaluate the quality of life and its correlation with sleep quality independently from the influence of pain or general health [5]. Questionnaires are a validated tool to assess global health or symptom severity [12, 13]. Lack of objectivity for the PSQI questionnaire was noticed in several trials, especially in specific subgroups like cancer patients [23]. So, some authors used to combine the questionnaire to sleep diaries, actigraphy, or polysomnography [24–26]. There is a shortage of studies dedicated to analyse sleep quality in lung or chest cancer patients generally. However, sleep quality in many other types and localizations of cancer was assessed (Table 7, Table 8). Particular attention was granted to advanced stages, symptomatic patients, and survivor patients [20, 22, 27, 28]. These studies noted high PSQI scores. The blunt impact of the sociodemographic factors, the remarkable correlation between good sleep quality, and quality of life suggest an outstanding impact of the disease and the anxiodepressive reaction coming with it. A damaged “body image” could explain this fact, even with neither pain nor worsening of performance status. Poor quality of life in gynecologic cancer was widely described, even in operated patients (Table 8).

After cancer treatment, the prevalence of poor sleep quality was usually between 54% and 79%. Results from the study of Ilhan et al. [29] illustrated the influence of therapeutic methods (surgery, chemotherapy, and radiation therapy) on sleep quality in endometrium cancer patients: the PSQI mean score moved from 4.6 before treatment to 8.1 after treatment and poor sleep quality prevalence rised from 28% to 79%.

The effect of therapeutic procedure in sleep quality of cancer patients was randomly noted in several studies (Table 8). This fact could be explained by the heterogeneity in objectives or in the inclusion criteria of various trials. However, other findings must be underlined: Utility of questionnaires as assessment tools in cancer patients, high prevalence of sleep disturbances in cancer patients, and persistence of these troubles after specific treatment or even in survivor patients after a curative procedure. In lung cancer patients, sleep disturbances could be a “late-onset” phenomenon, noted mainly after chemotherapy. The relationship between quality of life and sleep disturbances does not make doubt. It seems to be strengthened when it is associated to mood disturbances. Also, anxiodepressive humor was described as a predictive factor of a declined quality of life [30–32]. Authors suggested to screen for poor quality of life and for mood disturbances, then to set up a psycho-oncological support program managed by the same structures of treatment. Such a nonpharmacological treatment could be effective in a cluster of poor sleeping patients.

5. Conclusions

Interactions between sleep quality, sleep composition, immune system, homeostasis, and endocrine functions are mutual and complicated. So, sleep quality could have an indirect impact on psychological equilibrium, response to treatment disease progression, and prognosis. Preservation of sleep quality is a major palliative care increasingly mentioned in advanced cancer management. Nevertheless, sleep quality deterioration before and after chemotherapy of lung cancer wasn't studied. Assessment of sleep quality is usually forgotten by physicians. There is, till today, no clear recommendations for the treatment of insomnia. Our study described a statistically significant relation between sleep quality, quality of mood and quality of life before, and after chemotherapy in locally advanced NSCLC patients. Further prospective studies are still needed to establish evidence-based recommendations for the treatment of sleep disturbances in cancer patients.

Appendix

A.1. Pittsburgh Sleep Quality Index (PSQI) Questionnaire in English Version.

Pittsburgh Sleep Quality Index (PSQI) questionnaire in English version

INSTRUCTIONS:
The following questions relate to your usual sleep habits during the past month only. Your answers should indicate the most accurate reply for the majority of days and nights in the past month. Please answer all questions.

During the past month,

- How many times did you awaken during the night?
- How long did it take you to fall asleep?
- How long have you usually gotten up in the morning?
- How many times have you woken up during the night?
- How many times have you woken up during the night?

1. During the past month, how often have you had trouble sleeping because of:	No. of days trouble sleeping	Days per week	Score (0-3)	Days per week	Score (0-3)
A. Change in sleep habits					
B. Noise or other environmental factors					
C. Need to get up for work or school					
D. Sleep apnea or snoring					
E. Leg cramps					
F. Hot or cold					
G. Pain					
H. Medication					
I. Other					

2. During the past month, how often have you been unable to get up in the morning because of:

No. of days	Days per week	Score (0-3)	Days per week	Score (0-3)

3. During the past month, how many times have you had trouble sleeping because of:

No. of days	Days per week	Score (0-3)	Days per week	Score (0-3)

Arabic dialectal version is available from the corresponding author upon request.

A.2. PSQI Scoring

Scoring

Component 1: # of Sleep Disturbances (0-3) → C1
 Component 2: # of Sleep Latency (0-3) → C2
 Component 3: # of Hours Awakened (0-3) → C3
 Component 4: # of Waking Times (0-3) → C4
 Component 5: # of Sleep Efficiency (0-3) → C5
 Component 6: # of Sleep Duration (0-3) → C6
 Component 7: # of Sleep Quality (0-3) → C7

Add the seven component scores together. Global PSQI

A total score of 15 or greater is indicative of poor sleep quality.
 If you scored 15 or more it is suggested that you discuss your sleep habits with a healthcare provider.

A.3. QLQ-C30 Questionnaire in English Version

A.4. QLQ-C30 Scoring

All of the scales and single-item measures range in score from 0 to 100. A high score represents a higher symptom level.

This is a high score for a functional scale represents a high / healthy level of functioning.

A high score for the global health status / QoL represents a high QoL.

A high score for a symptom scale / item represents a high level of symptomatology / problem.

The principle for scoring these scales is the same in all cases:

- Estimate the average of the items that contribute to the scale; this is the raw score.
- Use a linear transformation to standardize the raw scores, so that scores range from 0 to 100; a higher score represents a higher patient's level of functioning, or a higher "overall" level of symptoms.

Scale	Number of items	Item range*	Version 3.0 Item weights	Functional scales
Global health status / QoL (Global health status QoL (GHS-QoL))	5	1-5	1	Y
Functional scales				
Physical functioning (PF)	5	1-5	1	Y
Role functioning (RF)	2	1-3	1	F
Emotional functioning (EF)	4	1-3	1	F
Cognitive functioning (CF)	2	1-3	1	F
Social functioning (SF)	3	1-3	1	F
Symptom scales / items				
Fatigue (FA)	3	1-3	1	N
Pain (PA)	2	1-3	1	N
Nausea and vomiting (NV)	2	1-3	1	N
Appetite loss (AP)	1	1-3	1	N
Constipation (CO)	1	1-3	1	N
Diarrhea (DI)	1	1-3	1	N
Insomnia (IS)	1	1-3	1	N

* Item range is the difference between the highest and lowest item scores. For the functional scales, a higher score represents a higher level of functioning. For the symptom scales, a higher score represents a higher level of symptomatology.

For all scales, the raw score is calculated as follows: $Raw\ score = \frac{\sum (item\ scores)}{number\ of\ items}$

Then for Functional scales: $Score = \frac{100 - (raw\ score - 1) \times 100}{3}$

and for Symptom scales / items and Global health status / QoL: $Score = \frac{(raw\ score - 1) \times 100}{3}$

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

Authors hereby declare having no conflict of interest in the study field.

Authors' Contributions

Belloumi did the research, data collection, investigation, and redaction; Maalej did the methodology, scientific reviewing, supervision, and validation; Bachouch did the supervision and validation; Chermiti and Fenniche did the methodology, supervision, and validation.

References

- 1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.
- 2] J. Ferlay, M. Colombet, I. Soerjomataram et al., "Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods," *International Journal of Cancer*, vol. 144, no. 8, pp. 1941–1953, 2019.
- 3] M. Ben Abdallah and W. Hizem Ben Ayoub, *Registre des cancers Nord Tunisie (2004 - 2006) [Internet]. ministère de la santé publique*, Disponible sur, Bab Saadoun, Tunisia, 2010, <http://www.insp.rns.tn/doc/cancer/cancer17.pdf>.
- 4] J.-P. Benezech, "Sleep troubles and cancer," *Médecine Palliative : Soins de Support - Accompagnement - Éthique*, vol. 9, no. 4, pp. 184–190, 2010.
- 5] P. Good, R. Pinkerton, S. Bowler, J. Craig, and J. Hardy, "Impact of opioid therapy on sleep and respiratory patterns in adults with advanced cancer receiving palliative care," *Journal of Pain and Symptom Management*, vol. 55, no. 3, pp. 962–967, 2018.
- 6] Y. Le Guen, F. Gagnadoux, J. Hureauux, N. Meslier, and J.-L. Racineux, "Sleep disorders and cancer," *Medicine du Sommeil*, vol. 5, no. 16, pp. 14–17, 2008.
- 7] J. K. Payne, B. F. Piper, I. Rabinowitz, and M. B. Zimmerman, "Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: a pilot study," *Oncology Nursing Forum*, vol. 33, no. 4, pp. 775–783, 2006.
- 8] N. S. Redeker, E. L. Lev, and J. Ruggiero, "Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy," *Scholarly Inquiry for Nursing Practice*, vol. 14, no. 4, pp. 275–290, 2000, discussion 291–298.
- 9] C. Miaskowski and K. A. Lee, "Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study," *Journal of Pain and Symptom Management*, vol. 17, no. 5, pp. 320–332, 1999.
- 10] R. Rami-Porta, V. Bolejack, J. Crowley et al., "The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer," *Journal of Thoracic Oncology*, vol. 10, no. 7, pp. 990–1003, 2015.
- 11] *Common Terminology Criteria for Adverse Events (CTCAE)*, U.S. Department of Health and Human Services, 2017, https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf#search=%22COMMON%20TERMINOLOGY%22.

- [12] D. J. Buysse, C. F. Reynolds III, T. H. Monk, S. R. Berman, and D. J. Kupfer, "The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research," *Psychiatry Research*, vol. 28, no. 2, pp. 193–213, 1989.
- [13] S. L. Beck, A. L. Schwartz, G. Towsley, W. Dudley, and A. Barsevick, "Psychometric evaluation of the Pittsburgh sleep quality index in cancer patients," *Journal of Pain and Symptom Management*, vol. 27, no. 2, pp. 140–148, 2004.
- [14] H. Ameri, M. Yousefi, M. Yaseri, A. Nahvijou, M. Arab, and A. A. Sari, "Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in colorectal cancer patients," *Journal of Gastrointestinal Cancer*, vol. 51, no. 1, pp. 196–203, 2020.
- [15] C. Bascoul-Mollevi, M. Savina, A. Anota et al., "Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command *qlqc30_TTD*," *Computer Methods and Programs in Biomedicine*, vol. 158, pp. 153–159, 2018.
- [16] F. Fiteni, I. L. Ray, A. Ousmen, N. Isambert, A. Anota, and F. Bonnetain, "Health-related quality of life as an endpoint in oncology phase I trials: a systematic review," *BMC Cancer*, vol. 19, no. 1, p. 361, 2019.
- [17] A. B. Smith, K. Cocks, D. Parry, and M. Taylor, "Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G)," *Quality of Life Research*, vol. 23, no. 3, pp. 971–976, 2014.
- [18] A. Masmoudi, M. Frikha, and J. Daoud, "Feasibility of quality of life assessment in routine clinical oncology practice: a Tunisian study," *Eastern Mediterranean Health Journal*, vol. 15, no. 2, pp. 362–368, 2009.
- [19] *Manuals [Internet]. EORTC – Quality of Life*, EORTC, 2019, <https://qol.eortc.org/manuals/>.
- [20] M. Miladinia, S. Baraz, M. Ramezani, and A. S. Malehi, "The relationship between pain, fatigue, sleep disorders and quality of life in adult patients with acute leukaemia: during the first year after diagnosis," *European Journal of Cancer Care*, vol. 27, no. 1, article e12762, 2018.
- [21] J. Savard and C. M. Morin, "Insomnia in the context of cancer: a review of a neglected problem," *Journal of Clinical Oncology*, vol. 19, no. 3, pp. 895–908, 2001.
- [22] S. Khemiri, J. Ben Thabet, W. Ben Kridis, M. Maalej, A. Khanfir, and M. Frikha, "Repercussions psychoaffectives de la douleur chez les patients cancéreux," *Cancer/Radiothérapie*, vol. 23, no. 3, pp. 188–193, 2019.
- [23] H.-M. Chen, Y.-C. Wu, C.-M. Tsai, J.-I. Tzeng, and C.-C. Lin, "Relationships of circadian rhythms and physical activity with objective sleep parameters in lung cancer patients," *Cancer Nursing*, vol. 38, no. 3, pp. 215–223, 2015.
- [24] C. Vena, K. P. Parker, R. Allen, D. L. Bliwise, S. Jain, and L. Kimble, "Sleep-wake disturbances and quality of life in patients with advanced lung cancer," *Oncology Nursing Forum*, vol. 33, no. 4, pp. 761–769, 2006.
- [25] K. P. Parker, D. L. Bliwise, M. Ribeiro et al., "Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography," *Journal of Clinical Oncology*, vol. 26, no. 15, pp. 2464–2472, 2008.
- [26] D. Fujisawa, J. S. Temel, J. A. Greer et al., "Actigraphy as an assessment of performance status in patients with advanced lung cancer," *Palliative and Supportive Care*, vol. 17, no. 5, pp. 574–578, 2019.
- [27] A. Musarezaie, F. Khaledi, H. N. Esfahani, and T. M. Ghaleghasemi, "Factors affecting quality of life and fatigue in patients with leukemia under chemotherapy," *Journal of Education Health Promotion*, vol. 3, p. 64, 2014.
- [28] P. M. Silberfarb, P. J. Hauri, T. E. Oxman, and P. Schnurr, "Assessment of sleep in patients with lung cancer and breast cancer," *Journal of Clinical Oncology*, vol. 11, no. 5, pp. 997–1004, 1993.
- [29] T. Tuyan İlhan, M. G. Uçar, A. Gül, T. Saymaz İlhan, G. Yavaş, and Ç. Çelik, "Sleep quality of endometrial cancer survivors and the effect of treatments," *Journal of Turkish Society of Obstetric and Gynecology*, vol. 14, no. 4, pp. 238–242, 2017.
- [30] J. C. Yi and K. L. Syrjala, "Anxiety and depression in cancer survivors," *Medical Clinics of North America*, vol. 101, no. 6, pp. 1099–1113, 2017.
- [31] M. J. Kim, I. Park, J. M. Park, K. H. Kim, J. Park, and D. W. Shin, "Systematic review and meta-analysis of initial management of pneumothorax in adults: intercostal tube drainage versus other invasive methods," *PLoS One*, vol. 12, no. 6, article e0178802, 2017.
- [32] L. Inhestern, V. Beierlein, J. C. Bultmann et al., "Anxiety and depression in working-age cancer survivors: a register-based study," *BMC Cancer*, vol. 17, no. 1, p. 347, 2017.
- [33] M. Delgado-Guay, S. Yennurajalingam, H. Parsons, J. L. Palmer, and E. Bruera, "Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer," *Journal of Pain and Symptom Management*, vol. 41, no. 5, pp. 819–827, 2011.
- [34] S. L. Beck, A. M. Berger, A. M. Barsevick, B. Wong, K. A. Stewart, and W. N. Dudley, "Sleep quality after initial chemotherapy for breast cancer," *Supportive Care in Cancer*, vol. 18, no. 6, pp. 679–689, 2010.
- [35] T. C. Mansano-Schlosser and M. F. Ceolim, "Association between poor clinical prognosis and sleep duration among breast cancer patients," *Revista Latino-Americana de Enfermagem*, vol. 25, 2017.
- [36] H. Kerner, N. Samuels, S. Ben Moshe, I. S. Sharabi, and E. Ben-Arye, "Impact of a patient-tailored complementary/integrative medicine programme on disturbed sleep quality among patients undergoing chemotherapy," *BMJ Support Palliat Care*, vol. 7, no. 2, pp. 98–108, 2017.
- [37] J. Fortmann, A. Fisher, R. Hough, A. Gregory, and G. Pugh, "Sleep quality, fatigue, and quality of life among teenage and young adult cancer survivors," *Journal of Adolescent and Young Adult Oncology*, vol. 7, no. 4, pp. 465–471, 2018.
- [38] C. Trudel-Fitzgerald, J. Savard, and H. Ivers, "Evolution of cancer-related symptoms over an 18-month period," *Journal of Pain and Symptom Management*, vol. 45, no. 6, pp. 1007–1018, 2013.
- [39] S. D. Armbruster, J. Song, L. Gatus, K. H. Lu, and K. M. Basen-Engquist, "Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis," *Gynecologic Oncology*, vol. 149, no. 1, pp. 133–139, 2018.